GlobeNewsWire
18 Jun 2026, 12:44 UTC · 19w ago
Berger Montague PC Investigating Claims on Behalf of ADMA Biologics, Inc. (NASDAQ: ADMA) Investors After Class Action Filing
Impact · against what's priced in
The announcement of class action lawsuits against ADMA, PICS, and BMI introduces significant legal and regulatory risk. ADMA is most severely impacted due to specific allegations of channel stuffing and artificial revenue inflation that contradict its reported growth figures.
- ADMA−0.90
No priced-in read yet





